Norsk Hydro, A.s.

Reidar Oftebro

John M Dornish

Rolf O Larsen

Erik O Pettersen

Bernt Borretzen

Thomas Ramdahl

Bernt Bo Slashedrretzen

Vidar Moen

Erick O Pettersen

Rold O Larsen

Bernt Boorretzen

Pharmaceutical compositions

New compounds having the general formula I ##STR1## wherein L may be H or D; Y may be CN or ##STR2## wherein A may be H, D, alkyl with 1-4 carbon atoms, OR wherein R is H or alkyl with 1-4 carbon atoms, or CR.sub.1 R.sub.2 R.sub.3 wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and are H or alkyl with 1-4 carbon atoms; Z is H, D, Y or alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms, or OR wherein R may be H or alkyl with 1-4 C-atoms, or CR.sub.4 R.sub.5 R.sub.6 wherein R.sub.4, R.sub.5 and R.sub.6 may be the same or different and may be H or F; X.sub.1 and X.sub.2 may be the same or different and may be OR, NR.sub.1 R.sub.2 or SR, wherein R, R.sub.1 and R.sub.2 may be the same or different and may be alkyl having 1-22 carbon atoms which may be branched or straight chained and/or may be further substituted; or X.sub.1 and X.sub.2 may together with the carbon atom to which they are bound form a cyclic acetal, thioacetal, dithiane, aminal, oxazolidine or thiazolidine; and pharmaceutically acceptable salts thereof. The compounds are useful as anti-cancer agents and as agents useful for the treatment of illnesses arising due to an abnormally elevated cell-proliferation.

Compounds

New compounds having the general formula I ##STR1## wherein Y may be H or D; and A is H, D, alkyl with 1-4 C-atoms, halogen, nitro, amino, monoalkyl amino or dialkyl amino wherein the alkyl groups have 1-4 C atoms or OR wherein R is H or alkyl of 1-4 C-atoms;

Acetal derivatives of aromatic aldehydes

New compounds of formula I: ##STR1## wherein Y may be CN or ##STR2## wherein A may be H, D, alkyl with 1-4 carbon atoms, OR wherein R is H or alkyl with 1-4 carbon atoms, or --NR.sub.1 R.sub.2 or --CR.sub.1 R.sub.2 R.sub.3 wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and are H or alkyl with 1-4 carbon atoms;

Deuterated benzaldehydes

The use of L-ascorbic acid, or a pharmaceutically acceptable salt thereof, in combination with 5,6-O-benzylidene-L-ascorbic acid, or 5,6-O-benzylidene-L-ascorbic acid deuterated at least at the 1-position of the aldehyde group of the benzylidene moiety, or a pharmaceutically acceptable salt of such acids, results in a synergistically enhanced cytotoxicity on human carcinoma cells.

Pharmaceutical compositions with anti-cancer activity against carcinoma

Anti-cancer platinum complexes such as cisplatin exhibit a synergistically higher level of anti-tumour activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.

Pharmaceutical compositions with anit-cancer activity and method for the

Anti-cancer platinum complexes such as cisplatin exhibit a synergistically high level of anti-tumor activity when administered substantially simultaneously either with L-ascorbic acid, or with 5,6-O-benzylidene-L-ascorbic acid or deuterated forms thereof.

Growing community of inventors

Hvalstad, Norway

Reidar Oftebro